CSL Plasma Device Switch|Terumo's US$610m Loss, Cheaper Plasma for CSL?

Who pays for the switch

CSL's plasma arm has agreed with Japan's Terumo to end their device supply deal, and plans to move its US centres to Haemonetics. Yet the loss that has surfaced sits with the supplier being dropped: Terumo expects a hit of about 610 million US dollars. Terumo has already revised its full-year guidance because of it. This is best read as CSL using its buying power to push the cost and risk of the switch onto suppliers.

It is not yet proof that CSL's own plasma collection costs will fall. For Terumo, this is no rounding error. It cut its net profit forecast for the year to March 2027 to 120 billion yen. The previous forecast was 193.1 billion yen. That is a cut of about 38 per cent, driven by the end of one contract. Operating profit guidance fell by 97.5 billion yen. That is almost exactly the size of the loss Terumo is booking.

Terumo's blood technology unit began working with CSL Plasma in 2021. It has supplied collection devices to CSL's centres in the United States. Plasma is the liquid part of blood that donors give at those centres. Manufacturers turn it into treatments for rare and chronic diseases. The machine is only the start of the revenue. Every donation uses single-use disposables, replaced for each donor.

They give device makers recurring revenue beyond the equipment sale. Under the new arrangement, it is CSL that buys those disposables. So a supplier's recurring revenue is CSL's recurring collection cost. After agreeing to end the deal, Terumo reassessed its future revenue from the business. The hit includes impairments on related assets and other expenses. Its revenue guidance moved down by just 9.5 billion yen.

Adjusted operating profit, which excludes one-off items, is unchanged at 274.5 billion yen. The contract ends only after an agreed transition period. In effect, Terumo is writing off years of per-donation spending by CSL that it no longer expects. That shows how large a cost line CSL controls.

A customer that can walk away

Where CSL is going makes the move stranger. Haemonetics is not a new supplier to CSL. According to Bank of America analyst Joanne Wuensch, CSL terminated its plasma supply agreement with Haemonetics in 2021. That is the same year Terumo's collaboration with CSL Plasma began. Losing CSL held Haemonetics' organic revenue growth to 1.1 per cent in fiscal 2026.

Without its CSL sales, one report calculated, growth would have been 9.5 per cent. Within about five years, CSL has walked away from both machine makers in this story. Each time, the supplier left behind took the visible damage. At Haemonetics, growth fell to near flat. At Terumo, the estimated cost is 610 million US dollars.

CSL runs one of the world's largest networks of plasma collection centres, as one market analysis put it. That looks like a customer the suppliers need more than it needs any one of them. CSL and Haemonetics signed their new agreement on 18 August 2026. It is non-exclusive. CSL may use Haemonetics' devices and buy the disposables in the US, while keeping other suppliers available.

Bank of America's analyst noted it has no minimum purchase requirements. Even the rollout is not fixed. Its scope and timing remain subject to change under the agreement, and implementation details have yet to be decided. Terumo's own announcement presents the exit as a joint decision.

It says the two sides "have mutually agreed to terminate their existing supply agreement following a mutually agreed transition period." Haemonetics, in its filing, stressed what remains open. The rollout's scope and timing could still change, it said, consistent with the agreement's terms. Neither statement says what CSL pays per donation. Neither says whether any money changed hands to end the Terumo contract.

Put the two contracts side by side. Terumo has already booked its loss for the current fiscal year. Haemonetics has a customer that promises no minimum volume. So the option to change course stays with CSL. For now, the cost of being wrong sits largely with the machine makers.

Whose margin rises

Then comes a fact that cuts against a clean bargaining win for CSL. Bank of America upgraded Haemonetics to Buy, citing the CSL deal. Its analyst wrote that the CSL contract "should provide upside to organic revenue growth, operating margins, and EPS". She made that conditional on a healthy plasma market. She lifted her price target from 92 to 123 US dollars.

Haemonetics shares rose about 13 per cent in regular trading after CSL's timetable came out. Wider margins at the supplier and lower costs at CSL can both be true at once. But none of these reports gives CSL's price per disposable kit. Nor do they give any saving CSL expects from the switch, or CSL's own reasons for choosing Haemonetics. So the cost half of the claim has to be pulled back.

The evidence supports a shift of risk onto suppliers. It does not yet show a lower bill for CSL. If part of the gain shows up first in a supplier's margins, CSL may be paying for some of it.

How far the switch goes

The scope of the switch is also described two ways. Nikkei Asia reported that CSL Plasma chose devices from elsewhere for some locations. Terumo's release speaks of the transition of "the affected centers", under a plan the two sides agreed. Haemonetics' filing says something larger. CSL currently anticipates the switch will cover all its current US centres, finishing by the end of 2027.

When Haemonetics first disclosed the deal in August, it expected CSL to switch only a portion of its US centres. Scope and timing were undecided. About seven weeks later, that portion with no date became every current centre, with a deadline. The key word is anticipates. It is an expectation CSL passed to Haemonetics, and the filing says it remains subject to change. So the claim splits by timing.

The risk shift has already happened. Terumo is booking it in this fiscal year. The full network move is a different matter. It would reshape what CSL pays per donation in the US, and it is an expectation running to the end of 2027. Until then, CSL keeps both doors open. Terumo's centres move on an agreed transition plan, and Haemonetics has no minimum order. Back to where this began.

A customer walked away, and a 610 million US dollar loss landed on the supplier. Weigh the write-down, the open-ended terms and CSL's record of leaving both suppliers. On balance, CSL has structured this switch in its own favour on risk. Whether that becomes cheaper plasma for CSL shareholders is still unproven. So far the visible gains sit with Haemonetics. The first hard signal will come from Haemonetics.

It has not updated its fiscal 2027 guidance. It will give the deal's expected impact at its November 2026 earnings call. If that update points to a fast, network-wide ramp, CSL is again tying its US collection to one supplier. Then the part of this reading that says CSL keeps the option weakens. In that case Haemonetics gains leverage over CSL's per-donation spending, and CSL gives up some freedom to switch.

A slow, partial ramp would mean CSL is still keeping both doors open.

Informational only, not investment advice. Figures and quotes come from the linked reports.